Disposition of 9648 shares by Simpson Curran of Regenxbio at 15.04 subject to Rule 16b-3
| RGNX Stock | USD 9.58 0.01 0.10% |
Slightly above 61% of Regenxbio's investor base is looking to short. The analysis of the overall investor sentiment regarding Regenxbio suggests that many traders are alarmed. Regenxbio's investing sentiment can be driven by a variety of factors including economic data, Regenxbio's earnings reports, geopolitical events, and overall market trends.
Regenxbio |
Filed transaction by Regenxbio Director, Officer: Chief Executive Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Regenxbio Fundamental Analysis
We analyze Regenxbio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Regenxbio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Regenxbio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Regenxbio is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Regenxbio Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Regenxbio stock to make a market-neutral strategy. Peer analysis of Regenxbio could also be used in its relative valuation, which is a method of valuing Regenxbio by comparing valuation metrics with similar companies.
Peers
Regenxbio Related Equities
| PASG | Passage Bio | 21.57 | ||||
| RNA | Avidity Biosciences | 4.35 | ||||
| ANTX | AN2 Therapeutics | 3.73 | ||||
| PLRX | Pliant Therapeutics | 3.70 | ||||
| QURE | Uniqure NV | 3.63 | ||||
| STOK | Stoke Therapeutics | 3.06 | ||||
| IMCR | Immunocore Holdings | 1.58 | ||||
| RVMD | Revolution Medicines | 1.32 | ||||
| CRNX | Crinetics Pharmaceuticals | 0.05 | ||||
| RCKT | Rocket Pharmaceuticals | 0.07 | ||||
| GLUE | Monte Rosa | 0.35 | ||||
| KZR | Kezar Life | 0.40 | ||||
| MIRM | Mirum Pharmaceuticals | 1.03 | ||||
| PTGX | Protagonist Therapeutics | 2.00 | ||||
| FDMT | 4D Molecular | 2.18 | ||||
| DAWN | Day One | 2.19 | ||||
| REPL | Replimune | 11.19 |
Additional Tools for Regenxbio Stock Analysis
When running Regenxbio's price analysis, check to measure Regenxbio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regenxbio is operating at the current time. Most of Regenxbio's value examination focuses on studying past and present price action to predict the probability of Regenxbio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regenxbio's price. Additionally, you may evaluate how the addition of Regenxbio to your portfolios can decrease your overall portfolio volatility.